Abstracts tagged "rheumatoid arthritis"

Abstract Number: 3148 • 2016 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Mandar Bawadekar¹, Daeun Shim¹, Ryan Rebernick¹, Chloe Peyton¹, Chad J. Johnson², Thomas F. Warner³, Dres Damgaard⁴, Claus Henrik Nielsen⁵, Anthony P. Nicholas⁶, Ger JM Pruijn⁷, Jeniel E. Nett⁸ and Miriam A. Shelef^1,9, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, ⁴Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁵Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁶Neurology, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ⁷Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands, ⁸Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, ⁹William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The presence of anti-citrullinated protein antibodies in rheumatoid arthritis points to a potential role for citrullination in disease pathogenesis. Peptidylarginine deiminases (PADs) catalyze the…
Abstract Number: 1111 • 2016 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Receptor Tyrosine Kinases Mediated Activity and Cell Invasiness in Fibroblast-like Synoviocytes
Teresina Laragione, Nasim Azizgolshani, Carolyn Harris, Erjing Gao and Percio Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is a new arthritis severity gene recently identified in the Pristane and Collagen-induced arthritis (PIA, CIA) quantitative trait locus Cia25/Pia42…
Abstract Number: 1435 • 2016 ACR/ARHP Annual Meeting
KCa1.1 Potassium Channels Are a Novel Therapeutic Target on Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Mark Tanner¹, Redwan Huq¹, Rajeev Tajhya¹, Michael Pennington², Teresina Laragione³, Pércio Gulko⁴ and Christine Beeton⁵, ¹Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, ²Peptides International, Louisville, KY, ³Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibroblast-like synoviocytes (FLS) develop a high degree of invasiveness during rheumatoid arthritis (RA), leading to joint degradation. There are currently no therapeutics that specifically…
Abstract Number: 1436 • 2016 ACR/ARHP Annual Meeting
TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis
Hiroaki Hayashi, Takafumi Harada, Shunsuke Demizu, Fumito Tatsuzawa, Ken Sato, Morihiro Mitsuya, Kenji Tanaka, Kazuhiko Yonekura, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: The family of Janus kinases (JAKs) plays important roles in signaling pathway mediated by various cytokine receptors. An aberrant activation of JAK-STAT signaling…
Abstract Number: 1447 • 2016 ACR/ARHP Annual Meeting
Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis
Ruth Davies¹, Jessica O Williams², Katie Sime², Ellyn Hughes², Lauren A. Jordan², Charlotte Rawlings², Derek Lang³, Stefan Rose-John⁴, Simon A. Jones⁵, Anwen S. Williams² and Ernest H. Choy^6,7, ¹CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Institute of Biochemistry, Christian Albrechts University, Kiel, Germany, ⁵Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, Wales, ⁶Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ⁷CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA), mainly due to cardiovascular disease (CVD). While molecular mechanisms underlining this clinical observation are unknown, systemic elevations…
Abstract Number: 1451 • 2016 ACR/ARHP Annual Meeting
Glutamine Metabolism Plays a Crucial Role in the Pathogenesis of Rheumatoid Arthritis
Soshi Takahashi¹, Jun Saegusa², Ikuko Naka³, Kosaku Tsuda³, Takaichi Okano⁴, Kengo Akashi³, Sho Sendo², Yo Ueda³, Akira Onishi⁵, Yoshinori Kogata² and Akio Morinobu², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Many signaling pathways activated under inflammatory and hypoxic conditions have profound effects on intracellular metabolism to support cell growth and survival. Cancer cells consume…
Abstract Number: 1462 • 2016 ACR/ARHP Annual Meeting
Magnesium Is a New Mediator Arthritis Severity and Joint Damage
Teresina Laragione, Nasim Azizgolshani, Carolyn Harris, Erjing Gao and Percio Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Given the effects of magnesium supplementation in suppressing components of the innate immunity in short-term studies, we examined the effect of dietary magnesium modifications…
Abstract Number: 1617 • 2016 ACR/ARHP Annual Meeting
Treatment with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, Improves Fatigue and Health-Related Physical and Emotional Well Being in Patients with Active Rheumatoid Arthritis Refractory to Conventional or Biologic Therapy: Results of 2 Global, Placebo-Controlled, Phase 3 Trials
Clifton Bingham III¹, Yoshiya Tanaka², George Karpouzas³, Tsutomu Takeuchi⁴, Daniel Aletaha⁵, Carter Thorne⁶, Shihong Sheng⁷, Weichun Xu⁷, Ravi Rao⁸, Kaiyin Fei⁷, Benjamin Hsu⁷, Prasheen Agarwal⁷, Sharon Popik⁷, Regina Kurrasch⁹, Steve Peterson⁷, Rita Ganguly⁹, Chenglong Han⁷ and Kelly McQuarrie⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ⁹GlaxoSmithKline, Collegeville, PA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience both substantial fatigue and a decline in their health-related physical and emotional well-being. Sirukumab is a…
Abstract Number: 1656 • 2015 ACR/ARHP Annual Meeting
Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment
Matthieu Lavielle¹, Denis Mulleman¹, Hsueh Cheng Sung², Clément Bahuaud², Philippe Goupille¹, Hervé Watier³ and Gilles Thibault³, ¹Service de Rhumatologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France, ²Université François-Rabelais de Tours, CNRS 7292, Tours, France, ³Laboratoire d'Immunologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France
Background/Purpose: CD4+ T-cell depletion after a first cycle of rituximab (RTX) in patients with rheumatoid arthritis (RA) was previously reported by our group (Mélet J…
Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Ernest H. Choy¹, Corrado Bernasconi², Maher Aassi², Jose F. Molina³ and Oscar M. Epis⁴, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Centro Integral de Reumatologia Reumalab, Medellin, Colombia, ⁴Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
Abstract Number: 1667 • 2015 ACR/ARHP Annual Meeting
Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Canestri, Clara Di Mario, Marcin Nowik and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for Rheumatoid Arthritis (RA) and it is a modifier of B cell subsets in vivo, inducing changes in…
Abstract Number: 175 • 2015 ACR/ARHP Annual Meeting
Correlating Semiquantitative Ultrasound Scores with Measured Synovial Thickness
Ralf G. Thiele¹, Darren Tabechian¹, Laura C Coates² and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine, University of Rochester, Rochester, NY
Background/Purpose: In studies of rheumatoid arthritis using ultrasonography (US), findings of synovial thickening are often reported in semiquantitative scores. For synovial biopsies of small joints,…
Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
Abstract Number: 450 • 2015 ACR/ARHP Annual Meeting
Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: It is well accepted that patients studied in pharmaceutically sponsored clinical trials do not always represent the types of patients seen in clinical practice. …
Abstract Number: 2012 • 2015 ACR/ARHP Annual Meeting
TNF Confers Pathogenic Memory in Synovial Fibroblasts Via Chromatin Remodeling, NF-Kb-Dependent Transcription and MAPK-Mediated mRNA Stabilization
Konstantinos Loupasakis¹, Christopher Sohn², Lionel B. Ivashkiv³ and George D. Kalliolias², ¹Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: We investigated mechanisms driving pathogenic behavior of synovial fibroblasts (FLS) in rheumatoid arthritis (RA). Methods: FLS from RA patients (1987 classification criteria) were extracted.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].